0001493152-24-012632.txt : 20240402 0001493152-24-012632.hdr.sgml : 20240402 20240402070007 ACCESSION NUMBER: 0001493152-24-012632 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240402 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OKYO Pharma Ltd CENTRAL INDEX KEY: 0001849296 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41386 FILM NUMBER: 24812183 BUSINESS ADDRESS: STREET 1: 55 PARK LANE CITY: LONDON STATE: X0 ZIP: W1K 1NA BUSINESS PHONE: 44 (0) 207 495 2379 MAIL ADDRESS: STREET 1: 55 PARK LANE CITY: LONDON STATE: X0 ZIP: W1K 1NA 6-K 1 form6-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April 2024

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On April 2, 2024, OKYO Pharma LTD (the “Company”) issued this 6K announcing, an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD

Date: April 2, 2024	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description

99.1		Press Release, dated April 2, 2024

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Logo, company name

Description automatically generated

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

London and New York, NY, April 2, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Eyecelerator Presenting Company Showcase – OKYO Pharma Presentation Details

Date: Thursday, April 4, 2024

Time: 1:00 – 2:30PM ET

Location:	Omni Boston Hotel at the Seaport – Level 2
	Ensemble Ballroom C, Breakout 1

Presenter: Gary Jacob, PhD, Chief Executive Officer

About Eyecelerator

Eyecelerator is a partnership between the American Academy of Ophthalmology and ASCRS to accelerate ophthalmic innovation through next-generation business conferences. Held the Thursday before each partner society’s annual meeting, Eyecelerator spurs innovation by connecting the scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who support their success. Eyecelerator conferences provide a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care. The conferences also provide valuable opportunities to network and explore new market potentials and the occasion for dozens of companies to present their novel clinical treatments and emerging technologies that are shaping the future of ophthalmology.

About OKYO

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.

Enquiries:

OKYO Pharma Limited	Gary S. Jacob, Chief Executive Officer	917-497-7560

Business Development & Investor Relations	Paul Spencer	+44 (0)20 7495 2379

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end